Patent classifications
G01N33/6845
METHODS FOR CONDUCTING MULTIPLEXED ASSAYS
The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.
MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF
The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
Ligand discovery for T cell receptors
Compositions and methods are provided for the identification of peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.
Ligand discovery for T cell receptors
Compositions and methods are provided for the identification of peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.
MACROMOLECULE ANALYSIS EMPLOYING NUCLEIC ACID ENCODING
A method for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding is disclosed.
HIGHLY PARALLEL ASSAYS FOR SIMULTANEOUS IDENTIFICATION OF ANTIBODY SEQUENCES AND BINDING PARTNERS
The present invention relates to methods for isolating the sequences of an antibody that reacts with a disease related antigen, e.g., an autoantigen, without knowing the identity of the antigen (sequence or structural epitope) a priori. The methods can also be used to identify an antigen that mediates a disease state, e.g., an autoantigen implicated in an autoimmune disorder or a tumor response.
AUTOMATED APPARATUS AND SYSTEM
The present disclosure provides sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Surface, anchored FC-bait antibody display system
The present invention provides, in part, an antibody display system that simultaneously uses a secretion and a display mode. A bait complexed with a monovalent antibody fragment can be expressed on the surface of the host cell wherein the fragment may be assayed for antigen binding while full antibody is simultaneously secreted from the host cell. Methods of using the system for identifying antibodies that bind specifically to an antigen of interest are also provided. Polypeptides, polynucleotides and host cells useful for making the antibody display system are also provided along with methods of use thereof.
METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES
The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.
Method for target protein identification using thermal stability shift-based fluorescence difference in two-dimensional gel electrophoresis
The present invention relates to a method for identifying a target protein using a thermal stability shift-based fluorescence difference in two-dimensional gel electrophoresis, and more specifically, a method for identifying a protein, which is a target of a specific drug, by analyzing, by means of a fluorescence difference in two-dimensional gel electrophoresis, a thermal stability shift in the protein when a specific drug, preferably a bioactive molecule, binds to the target protein.